Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
24 September 2022 - 6:05AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that
Peter Soparkar, chief operating officer of Adverum Biotechnologies,
will present at the Jefferies Cell and Genetic Medicine Summit on
September 29, 2022, at 9:30 a.m. ET.
The on-demand webcast corporate presentation may be accessed
under Events and Presentations in the Investors section
of Adverum’s website. A replay of the webcast will be available on
the website for 90 days following the presentation.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases with the aspiration of
developing functional cures to restore vision and prevent
blindness. Leveraging the research capabilities of its proprietary,
intravitreal (IVT) platform, Adverum is developing durable,
single-administration therapies, designed to be delivered in
physicians’ offices, to eliminate the need for frequent ocular
injections to treat these diseases. Adverum is evaluating its novel
gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly
referred to as ADVM-022), as a one-time, IVT injection for patients
with neovascular or wet age-related macular degeneration. By
overcoming the challenges associated with current treatment
paradigms for these debilitating ocular diseases, Adverum aspires
to transform the standard of care, preserve vision, and create a
profound societal impact around the globe. For more information,
please visit www.adverum.com.
Corporate & Investor Inquiries
Anand ReddiVice President, Head of Corporate Strategy, External
Affairs and EngagementAdverum Biotechnologies, Inc.T:
650-649-1358E: areddi@adverum.com
Media
Megan TalonAssociate Director, Corporate CommunicationsAdverum
Biotechnologies, Inc.T: 650-649-1006E: mtalon@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024